CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) CEO Xingjuan Chao sold 2,199 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $25.00, for a total transaction of $54,975.00. Following the completion of the sale, the chief executive officer owned 819,214 shares in the company, valued at $20,480,350. The trade was a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Xingjuan Chao also recently made the following trade(s):
- On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The stock was sold at an average price of $25.03, for a total transaction of $786,317.45.
- On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $19.90, for a total transaction of $776,100.00.
- On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total value of $714,870.00.
CeriBell Price Performance
Shares of NASDAQ:CBLL traded down $0.58 on Thursday, reaching $24.31. 262,277 shares of the company traded hands, compared to its average volume of 346,888. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $25.33. The company’s 50 day moving average is $19.30 and its 200-day moving average is $19.16. The stock has a market capitalization of $932.97 million, a PE ratio of -13.81 and a beta of 0.81. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79.
Institutional Investors Weigh In On CeriBell
Several hedge funds have recently bought and sold shares of CBLL. Strs Ohio purchased a new position in CeriBell during the 1st quarter valued at about $27,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell during the third quarter valued at approximately $33,000. CWM LLC grew its position in CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after purchasing an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares during the period.
Wall Street Analyst Weigh In
CBLL has been the topic of a number of analyst reports. BTIG Research lifted their price target on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday. Barclays raised shares of CeriBell to a “neutral” rating in a research note on Tuesday. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Finally, Canaccord Genuity Group boosted their price target on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, CeriBell has an average rating of “Moderate Buy” and a consensus price target of $22.40.
Get Our Latest Analysis on CeriBell
About CeriBell
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Featured Articles
- Five stocks we like better than CeriBell
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
